{"log_id": 3860530703448341410, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.014374, "average": 0.921845, "min": 0.572682}, "location": {"width": 792, "top": 258, "height": 54, "left": 249}, "words": "能需要减少瑞格列余的用药剂量,在同一所究中,格列奈与言贝齐和"}, {"probability": {"variance": 0.056566, "average": 0.777392, "min": 0.426567}, "location": {"width": 290, "top": 283, "height": 38, "left": 1155}, "words": "曲康半合显小出"}, {"probability": {"variance": 0.042057, "average": 0.820418, "min": 0.413113}, "location": {"width": 865, "top": 310, "height": 59, "left": 251}, "words": "的降作用,瑞格州奈AL.C增加19.4倍,半衰从13小时延长到6.小时"}, {"probability": {"variance": 0.017857, "average": 0.899937, "min": 0.384908}, "location": {"width": 1149, "top": 365, "height": 68, "left": 296}, "words": "甲氧啶(每日两次,每次160mg)是一种弱CY2C8抑制,与格奈(单剂0.5mg>同服,可"}, {"probability": {"variance": 0.009944, "average": 0.930355, "min": 0.710507}, "location": {"width": 134, "top": 424, "height": 27, "left": 244}, "words": "格列奈AUC"}, {"probability": {"variance": 0.020544, "average": 0.942752, "min": 0.35059}, "location": {"width": 466, "top": 424, "height": 47, "left": 445}, "words": "和生物衰期有轻微的增加4分别为16倍"}, {"probability": {"variance": 0.02322, "average": 0.881089, "min": 0.460058}, "location": {"width": 463, "top": 440, "height": 45, "left": 968}, "words": "倍1.2倍》,血水平增加无明显的统计学"}, {"probability": {"variance": 0.013891, "average": 0.933503, "min": 0.449236}, "location": {"width": 1199, "top": 475, "height": 68, "left": 239}, "words": "差异,这些缺少药效学结果的数据系根据瑞格列奈低剂黛治疗获得:由于尚无格列奈剂量高于0.25mg与甲氧"}, {"probability": {"variance": 0.021024, "average": 0.905191, "min": 0.467655}, "location": {"width": 1197, "top": 527, "height": 66, "left": 242}, "words": "苄润量高于320rug的合安全性数据,因此应避免将格列奈与甲氧苄氨嘧症合用,如果必须合用,应严密"}, {"probability": {"variance": 0.022891, "average": 0.900387, "min": 0.540282}, "location": {"width": 500, "top": 580, "height": 50, "left": 235}, "words": "监测患者的血糖水平,并进行严密的临因测"}, {"probability": {"variance": 0.027152, "average": 0.898707, "min": 0.378721}, "location": {"width": 1137, "top": 637, "height": 66, "left": 285}, "words": "利福平是一种CYP3A4强诱导剂:也延CYP2C8诱导剂,在瑞格州余的谢过程中同时起诱导科制作用"}, {"probability": {"variance": 0.031014, "average": 0.90171, "min": 0.550036}, "location": {"width": 125, "top": 692, "height": 29, "left": 230}, "words": "使用利裙平"}, {"probability": {"variance": 0.012193, "average": 0.926346, "min": 0.522272}, "location": {"width": 964, "top": 696, "height": 61, "left": 468}, "words": "先期治疗7天,然后与瑞将列禁(单4mg)在第7天时台用,AUC降低了50%《这是"}, {"probability": {"variance": 0.027674, "average": 0.901512, "min": 0.42535}, "location": {"width": 1201, "top": 744, "height": 66, "left": 228}, "words": "号利抑制作用的共同结果在最后一次服用利描平24小时后服用瑞格列奈:格列奈的AUC降低了E0%单"}, {"probability": {"variance": 0.02732, "average": 0.881317, "min": 0.554209}, "location": {"width": 125, "top": 801, "height": 29, "left": 226}, "words": "独诱导作用"}, {"probability": {"variance": 0.026957, "average": 0.89669, "min": 0.370934}, "location": {"width": 1110, "top": 854, "height": 66, "left": 276}, "words": "利平与格杂合可能会降低瑞格列亲的压药剂量,应产测患考在开始使用利福平快速抑制"}, {"probability": {"variance": 0.013132, "average": 0.935588, "min": 0.402077}, "location": {"width": 1201, "top": 909, "height": 68, "left": 221}, "words": "增加剂量〔混合抑制和选导和停用利福平单独诱导)以及停用利福平约1周后,其诱导作用消时的血水"}, {"probability": {"variance": 0.036939, "average": 0.867497, "min": 0.400693}, "location": {"width": 509, "top": 964, "height": 50, "left": 219}, "words": "平,并根据血糖水平调节格列奈的使用剂"}, {"probability": {"variance": 0.019685, "average": 0.916482, "min": 0.427134}, "location": {"width": 948, "top": 1021, "height": 61, "left": 269}, "words": "克拉霉素是一种CYP3A4抑制剂,以每日两次,每次250mg剂最与格列奈(单剂0"}, {"probability": {"variance": 0.010012, "average": 0.935145, "min": 0.739165}, "location": {"width": 123, "top": 1053, "height": 29, "left": 1297}, "words": "同服,可使"}, {"probability": {"variance": 0.032125, "average": 0.870316, "min": 0.382091}, "location": {"width": 539, "top": 1073, "height": 52, "left": 214}, "words": "洛列的暴露量有微弱的增加(AUC增1.4倍"}, {"probability": {"variance": 0.017853, "average": 0.885457, "min": 0.596267}, "location": {"width": 548, "top": 1094, "height": 47, "left": 811}, "words": "增如1.7倍冫,血清楼岛素AUC平均增值增加15倍"}, {"probability": {"variance": 0.000129, "average": 0.992493, "min": 0.970063}, "location": {"width": 137, "top": 1133, "height": 29, "left": 214}, "words": "增加16倍"}, {"probability": {"variance": 0.039212, "average": 0.812473, "min": 0.360829}, "location": {"width": 1155, "top": 1187, "height": 68, "left": 258}, "words": "服用碱格列奈(单次药4rg的同时用CYPA4制剂南康唑(每日200g),可在一定范围内常"}, {"probability": {"variance": 0.025905, "average": 0.886769, "min": 0.395675}, "location": {"width": 801, "top": 1242, "height": 57, "left": 210}, "words": "格列系的暴露量(AUC增加1.2倍,Cmu增加1.5倍),血糖变化8"}, {"probability": {"variance": 0.038228, "average": 0.857029, "min": 0.369427}, "location": {"width": 1158, "top": 1299, "height": 68, "left": 253}, "words": "璜格列奈与西米替、苯地平成辛伐包订合用,所有CYP3A4作底物均木显改变瑞格列的药代动"}, {"probability": {"variance": 0.002916, "average": 0.964684, "min": 0.871186}, "location": {"width": 100, "top": 1354, "height": 31, "left": 205}, "words": "力学参数"}, {"probability": {"variance": 0.01885, "average": 0.92108, "min": 0.491337}, "location": {"width": 1139, "top": 1411, "height": 63, "left": 253}, "words": "在健康志愿者中进行的药物相互作用研究发现,湍咯列奈对高辛、茶碱和法华林的药代动力学特性无影响"}, {"probability": {"variance": 0.002469, "average": 0.966347, "min": 0.822734}, "location": {"width": 619, "top": 1464, "height": 50, "left": 205}, "words": "闪此在与瑞格列奈联使用时,无需整这些药物的剂量"}, {"probability": {"variance": 0.020365, "average": 0.927417, "min": 0.473579}, "location": {"width": 1155, "top": 1521, "height": 66, "left": 249}, "words": "在康志者中开展的一项药代动力学究表,合出口服进孕药乙炔二左炔诺孕)虽然会缩短"}, {"probability": {"variance": 0.02088, "average": 0.904266, "min": 0.363816}, "location": {"width": 1206, "top": 1574, "height": 68, "left": 194}, "words": "瑞格列奈的达峰时间,但不会改变瑞格列的总生物利用度至相关临床范围。瑞格列茶对左块诺孕酮的物利出"}, {"probability": {"variance": 0.025582, "average": 0.898664, "min": 0.390015}, "location": {"width": 795, "top": 1631, "height": 52, "left": 194}, "words": "度没有具临床意义的影响,但不能排除对乙炔一醇的生物利用度的影响"}, {"probability": {"variance": 0.034181, "average": 0.845194, "min": 0.460833}, "location": {"width": 559, "top": 1685, "height": 50, "left": 244}, "words": "下列药物可能增强和或延长格列奈的降血砂f"}, {"probability": {"variance": 0.005554, "average": 0.925099, "min": 0.850572}, "location": {"width": 185, "top": 1676, "height": 82, "left": 1112}, "words": "江苏"}, {"probability": {"variance": 0.031674, "average": 0.839998, "min": 0.360246}, "location": {"width": 1034, "top": 1733, "height": 73, "left": 239}, "words": "占十贝齐,克拉标,醒唑,世康唑,氧苄症,其他类型抗尿病泰业"}, {"probability": {"variance": 0.002046, "average": 0.954768, "min": 0.909537}, "location": {"width": 182, "top": 1765, "height": 38, "left": 1208}, "words": " fp-al4f(MAD)"}, {"probability": {"variance": 0.034417, "average": 0.847798, "min": 0.374471}, "location": {"width": 1078, "top": 1781, "height": 84, "left": 185}, "words": "北选齐性B爱体胆滞剂血管紧张转换酶(ACE3剂,酒精以及是合成代限公司"}, {"probability": {"variance": 0.0264, "average": 0.885935, "min": 0.465115}, "location": {"width": 447, "top": 1855, "height": 43, "left": 242}, "words": "外药物可能碳弱瑞格列奈的降血糖用"}, {"probability": {"variance": 0.031443, "average": 0.85245, "min": 0.470964}, "location": {"width": 1151, "top": 1905, "height": 73, "left": 235}, "words": "口服避孕药,利业,苯巴比妥利卡马平,嗪类药物,皮质激索,达那唑,甲状腺激茶,奥曲肽和拟交"}], "language": 3}